Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice
Guillaume Darrasse-Jèze, … , Katrina Podsypanina, David Klatzmann
Guillaume Darrasse-Jèze, … , Katrina Podsypanina, David Klatzmann
Published August 3, 2009
Citation Information: J Clin Invest. 2009;119(9):2648-2662. https://doi.org/10.1172/JCI36628.
View: Text | PDF
Research Article Immunology

Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice

  • Text
  • PDF
Abstract

Early responses of Tregs and effector T cells (Teffs) to their first encounter with tumor cells have been poorly characterized. Here we have shown, in both implanted and in situ–induced mouse tumor models, that the appearance of tumor cells is immediately sensed by CD44hi memory Tregs that are specific for self antigens. The rapid response of these Tregs preceded and prevented activation of naive antitumor Teffs. The relative speed of the Treg versus the Teff response within the first 2–4 days determined the outcome of the antitumor immune response: tolerance or rejection. If antitumor memory Teffs were present at the time of tumor emergence, both Tregs and Teffs were recruited and activated with memory kinetics; however, the Tregs were unable to control the Teffs, which eradicated the tumor cells. This balance between effector and regulatory responses did not depend on the number of Tregs and Teffs, but rather on their memory status. Thus, in the natural setting, dominant tolerogenic immunosurveillance by self-specific memory Tregs protects tumors, just as it protects normal tissues. More generally, our results reveal that the timing of Treg and Teff engagement, determined by their memory status, is an important mode of regulation of immune responses.

Authors

Guillaume Darrasse-Jèze, Anne-Sophie Bergot, Aurélie Durgeau, Fabienne Billiard, Benoît L. Salomon, José L. Cohen, Bertrand Bellier, Katrina Podsypanina, David Klatzmann

×

Figure 1

Tumor emergence favors a Treg response that blocks efficient antitumor immune responses.

Options: View larger image (or click on image) Download as PowerPoint
Tumor emergence favors a Treg response that blocks efficient antitumor i...
(A, B, D, and E) CD4+ gated T cells were analyzed for CD25 and Foxp3 expression by flow cytometry. Control nLNs were taken from normal mice. dLNs and ndLNs of tumor-bearing mice were obtained at the indicated times after s.c. inoculation of 105 4T1 tumor cells in BALB/c mice (A and B) or B16F10 tumor cells in C57BL/6 mice (D and E). (A and D) CD25 and Foxp3 flow cytometry profiles of CD4+ T cells. Numbers indicate percentage of cells in the respective quadrants. (B) Absolute number of Tregs in 4T1-inoculated dLNs versus ndLNs at indicated times (P < 0.001). Fold increases compared with nLNs are indicated above each time point (3 mice per time point). (E) Mean percentage of CD4+CD25+Foxp3+ Tregs within CD4+ T cells, and absolute number of Tregs, in B16F10-inoculated dLNs versus nLNs at day 20 (P < 0.001). (C and F) Effect of Treg depletion on tumor growth. BALB/c (C) and C57BL/6 mice (F) were depleted of Tregs by anti-CD25 Ab treatment and challenged 5 days later with 105 4T1 or 2 days later with 105 B16F10 tumor cells, respectively. Kaplan-Meyer survival rate was significantly higher (C, P = 0.02; F, P < 0.001) in the anti-CD25–treated (n = 8 [C]; 14 [F]) than in the PBS-treated group (n = 5 [C]; 9 [F]). For each model, 1 representative of 5 independent experiments is shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts